Merged Company Provides Growth Platform for Products Targeting Improved Joint Related Conditions

Share Article

LifeGuard Health, the leader in condition specific Omega-3 products announced today its merger with PRN Nutriceuticals (PRN). PRN was established by prominent orthopedic surgeons to provide safe and effective alternatives to Cox II inhibitors and regular NSAID use. A new subsidiary, OmegaArthro Health, LLC has been formed.

As part of our specialty focused model, we have created a new subsidiary of LifeGuard Health for the musculoskeletal area. Our affiliation with these nationally prominent physician groups will serve as a springboard for expansion into the orthopedic market nationally

LifeGuard Health, the leader in condition specific Omega-3 products announced today its merger with PRN Nutriceuticals (PRN). PRN was established by prominent orthopedic surgeons to provide safe and effective alternatives to Cox II inhibitors and regular NSAID use. PRN had established a national network of physicians who recommended its products. LifeGuard Health has established itself as a market leader in the development and marketing of condition specific Omega 3 products through physicians. According to Peter Sharkey, MD, a cofounder of PRN, "the merger with LifeGuard Health will provide the management infrastructure needed to accommodate more rapid growth".

A new subsidiary, OmegaArthro Health, LLC has been formed. Kenneth A. Krieg, LifeGuard Health's CEO, and Robert D. Bauer, LifeGuard Health's President, have been named the Chief Executive Officer and President, respectively, of the new subsidiary. This company will be co-located with Lifeguard's corporate headquarters in Plymouth Meeting, Pennsylvania. According to Kenneth Krieg: "OmegaArthro Health will provide a platform for a more aggressive expansion into the orthopedic and musculoskeletal specialty areas, including physiatry, rheumatology, and chiropractic".

Clinical research supports that the Omega-3 eicosapentaenoic acid (EPA), a natural anti-inflammatory, improves pain outcomes with respect to patient assessed pain, duration of morning stiffness and number of painful and/or tender joints. Recent studies also provide empirical evidence to support the safe and effective use of omega-3 (EPA and DHA) in reducing joint pain associated with inflammatory conditions including rheumatoid arthritis (RA). OmegaArthro Health will use this growing body of medical evidence to support its product development strategy.(1)

"As part of our specialty focused model, we have created a new subsidiary of LifeGuard Health for the musculoskeletal area. Our affiliation with these nationally prominent physician groups will serve as a springboard for expansion into the orthopedic market nationally", stated Robert D. Bauer, President of OmegaArthro Health.

OmegaArthro Health products, as with all LifeGuard Health products, are manufactured in Triglyceride (TG) form for maximum absorption and bioavailability.
For additional information, contact Robert Bauer or visit http://www.OmegaArthroHealth.com.

Robert D. Bauer
President
OmegaArthro Health and
LifeGuard Health, LLC
610-862-0182
http://www.lifeguardforlife.com

(1) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Web Master
Visit website